You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Men with Biochemically Relapsed Hormone Sensitive Prostate Cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Castration Sensitive Prostate Cancer Trial in New York (Degarelix, Ipilimumab, Radical Prostatectomy)

Active, not recruiting
  • Metastatic Castration Sensitive Prostate Cancer
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Aug 4, 2022

Castration Sensitive Prostate Cancer Trial in Little Rock (Metformin, Turmeric)

Not yet recruiting
  • Castration Sensitive Prostate Cancer
  • Little Rock, Arkansas
    University of Arkansas for Medical Sciences
Sep 12, 2023

Metastatic Hormone-Sensitive Prostate Cancer Trial (Rezvilutamide, Rezvilutamide plus abiraterone, Continue previous treatment)

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer
  • (no location specified)
Nov 10, 2023

Oligometastatic Prostate Cancer Trial in New York (Quemliclustat, Etrumadenant, Zimberelimab)

Not yet recruiting
  • Oligometastatic Prostate Cancer
  • New York, New York
    Columbia University Irving Medical Center / NewYork-Presbyterian
Jun 14, 2023

Learn More About How Safe Darolutamide is Under Real-world

Not yet recruiting
  • Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
  • No Intervention
  • Multiple Locations, Japan
    Many Locations
Aug 24, 2023

Metastatic Prostate Cancer, Hormone Sensitive Prostate Cancer, Chemo Effect Trial in Nanjing (Docetaxel, Rezvilutamide)

Recruiting
  • Metastatic Prostate Cancer
  • +2 more
  • Nanjing, Jiangsu, China
    Urology dpt, First Affiliated Hospital of Nanjing Medical Univer
Aug 2, 2023

Apalutamide in Metastatic Hormone Sensitive Prostate Cancer

Not yet recruiting
  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
    • Cardiff, United Kingdom
    • +4 more
    Aug 25, 2023

    Prostate Cancer Trial in United States (ARN-509, LHRH Agonist)

    Completed
    Has Results
    • Prostate Cancer
    • Scottsdale, Arizona
    • +4 more
    Feb 27, 2020

    Metastatic Hormone-sensitive Prostate Cancer Trial in United States (Darolutamide (BAY1841788, Nubeqa), ADT)

    Recruiting
    • Metastatic Hormone-sensitive Prostate Cancer
    • Darolutamide (BAY1841788, Nubeqa)
    • ADT
    • Homewood, Alabama
    • +11 more
    Jan 13, 2023

    Prostate Cancer Trial ([18F]-PSMA-1007)

    Not yet recruiting
    • Prostate Cancer
    • [18F]-PSMA-1007
    • (no location specified)
    Jan 30, 2023

    Prostate Cancer, Radiotherapy Side Effect, Metastatic Cancer Trial in Umeå (Moderate hypo-fractionation,

    Recruiting
    • Prostate Cancer
    • +2 more
    • Moderate hypo-fractionation
    • Ultra-hypo-fractionation
    • Umeå, Sweden
      Cancercenter University hospital of Umeå
    Nov 1, 2022

    High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) Trial (dalpiciclib isethionate tablets; abiraterone acetate

    Not yet recruiting
    • High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC)
    • dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets
    • placebo; abiraterone acetate tablets; prednisone tablets
    • (no location specified)
    Oct 20, 2023

    Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy Trial in France (Abiraterone)

    Completed
    • Biochemically-relapsing Prostate Adenocarcinoma Following Radical Prostatectomy
    • Bordeaux, France
    • +4 more
    May 18, 2022

    Prostate Cancer Trial in Utrecht (PSMA-PET/CT response evaluation)

    Not yet recruiting
    • Prostate Cancer
    • PSMA-PET/CT response evaluation
    • Utrecht, Netherlands
      Roderick van den Bergh
    Sep 10, 2022

    Prostate Cancer Trial in Chicago (Docetaxel, ADT, Abiraterone)

    Not yet recruiting
    • Prostate Cancer
    • Chicago, Illinois
      Northwestern University
    Sep 27, 2023

    Oligometastatic Hormone Sensitive Prostate Cancer Trial in Florence (SBRT on all sites of metastatic disease+Apalutamide)

    Not yet recruiting
    • Oligometastatic Hormone Sensitive Prostate Cancer
    • SBRT on all sites of metastatic disease+Apalutamide
    • Florence, Italy
      AOU Careggi Radiation Oncology Unit
    Jan 29, 2023

    Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

    Recruiting
    • Biochemically Recurrent Prostate Carcinoma
    • Prostate Adenocarcinoma
    • Durvalumab
    • +3 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Jan 26, 2023

    Prostate Cancer Trial in Darlinghurst (SUBA-itraconazole, Hydroxychloroquine)

    Recruiting
    • Prostate Cancer
    • Darlinghurst, New South Wales, Australia
      St Vincent's Hospital
    May 3, 2022

    Hormone Sensitive Metastatic Prostate Cancer, DNA Damage Repair Deficiency, Chemo Effect Trial in Nanjing (Docetaxel,

    Recruiting
    • Hormone Sensitive Metastatic Prostate Cancer
    • +3 more
    • Nanjing, Jiangsu, China
      Department of Urology, Drum Tower Hospital, Medical School of Na
    Jul 13, 2022

    Metastatic Hormone Refractory Prostate Cancer Trial in Saint Louis (Cabozantinib, Nivolumab, Abiraterone acetate)

    Recruiting
    • Metastatic Hormone Refractory Prostate Cancer
    • Saint Louis, Missouri
      Washington University School of Medicine
    Jun 6, 2022

    Based Discrete Choice Experiment Study in Prostate Cancer Study

    Completed
    • Prostate Cancer
    • Metastatic Hormone-sensitive Prostate Cancer
      • Durham, North Carolina
        Duke Clinical Research Institute
      Jan 10, 2023

      Called AWARENESS Using Data From Alberta to Observe Treatment

      Active, not recruiting
      • Metastatic Castration-sensitive Prostate Cancer
      • ADT (Eligard®*) with or without treatment intensification
      • Multiple Locations, Alberta, Canada
      • +1 more
      Aug 1, 2022

      Prostate Cancer Metastatic Trial in New York (Actinium-J591, Stereotactic Body Radiation Therapy, Androgen Deprivation Therapy)

      Not yet recruiting
      • Prostate Cancer Metastatic
      • New York, New York
        Weill Cornell Medicine - New York Presbyterian Hospital
      Oct 3, 2022

      Metastatic Hormone-Sensitive Prostate Cancer Trial in Saint Louis (biological, drug, device, procedure)

      Completed
      • Metastatic Hormone-Sensitive Prostate Cancer
      • PROSTVAC-V
      • +9 more
      • Saint Louis, Missouri
        Washington University School of Medicine
      Aug 3, 2022

      Prostate Cancer Trial (Dutasteride, Abiraterone)

      Not yet recruiting
      • Prostate Cancer
      • (no location specified)
      Jan 30, 2023